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Abstract
Despite widespread agreement that nursing homes’ use of antipsychotic medications for residents without specific
psychiatric diagnoses is a marker of poor quality of care, prevalence remains high. Additionally, variation suggests
continued opportunity to improve care even in countries, like the United States, that have long-standing policies
designed to decrease antipsychotic medication use. In a recent Israel Journal of Health Policy Research article,
Frankenthal et al. presented results linking increased antipsychotic medication use prevalence in Tel Aviv nursing
homes with facility characteristics, including some that “undermine quality of care,” and called for increased national focus
on this area. While we agree with the authors that government focus can help to decrease antipsychotic medication use,
experience in the United States shows that such efforts may not be sufficient: we present data showing significant
variation among United States nursing homes’ antipsychotic medication use prevalence after more than ten years of
national warnings and programs. This suggests that United States nursing home clinicians and caregivers continue to
need effective non-pharmacologic interventions to substitute for antipsychotic medications. We suggest expanded use
of cluster-randomized trials to test strategies to withdraw residents from antipsychotic medications and to implement
alternate, non-pharmacological approaches for addressing the behavioral and psychological symptoms of dementia.
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Main text
The off-label use of antipsychotic medications to address
the behavioral and psychological symptoms of dementia is
controversial, because antipsychotic medications may in-
crease older adults’ risk of heart failure, sudden death, and
pneumonia [1, 2]. As a result, nursing homes’ use of
antipsychotics as chemical restraints for the purpose of
behavioral control is widely considered inappropriate,
absent a psychiatric diagnosis, and is increasingly con-
sidered to be a marker of poor quality of care. Despite
general agreement that non-pharmacological approaches
are preferable, studies in Europe [3], Canada [4], the
United States [5, 6], and elsewhere show that anti-
psychotic medication use remains highly prevalent in this
setting with evidence of substantial variation between
facilities [5, 7] and between countries [3, 8].
Understanding this variation can inform programs and
policies intended to reduce antipsychotic medication use.
The SHELTER study compared treatment of nursing
home residents in seven European countries and Israel,
and found that 32% of residents with a dementia diagnosis
had an antipsychotic prescription; prevalence ranged from
18% in Israel to 60% in the Czech Republic [3]. However,
this study only included a relatively small number of
volunteer facilities in each country, with considerable
intra-country variation. In a recent Israel Journal of Health
Policy Research (IJHPR) article, Frankenthal et al. [7] pre-
sented results linking increased APM prevalence among
Tel Aviv nursing homes with facility characteristics,
including some that “undermine quality of care.” These
included the presence of medical directors without spe-
cialized geriatrics training, shortages of social workers and
occupational therapists, and the use of unsafe or non-
fitting self-aid equipment [7]. The authors argue that their
findings shed light on a problematic care process, making
it transparent in a country where antipsychotic medication
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use is not regulated or publicly reported, and call for in-
creased national focus on this area.
In the United States, there has been a national spotlight
on reducing nursing home antipsychotic medication use
since our country’s Food and Drug Administration issued a
“boxed warning” against the use of these medications for
off-label indications among older adults, in 2005 [1]. More
recently, the Centers for Medicare & Medicaid Services
began publicly reporting nursing home antipsychotic medi-
cation rates on its Nursing Home Compare website (in
2011) [9] and implemented a national campaign to lower
use (in 2012) [10]. Although national prevalence has de-
creased over the past 10 years, our analysis of longitudinal
data available through Brown University’s LTCFocus.org
database [11] illustrates significant, ongoing variation in
facility-level antipsychotic medication prevalence (Fig. 1)
and suggests continued need for intervention in the United
States. While there are many nursing facilities with no resi-
dents (or virtually none) taking antipsychotics, even in
2014 there were hundreds of facilities with 40% or more of
their residents prescribed these medications.
To reduce nursing home antipsychotic medication use,
clinicians must implement strategies to identify and dis-
continue inappropriate off-label use among residents
with existing prescriptions [12] and practices to avoid
new prescriptions when the behavioral and psychological
symptoms of dementia become manifest [13]. Both ap-
proaches require alternative techniques so that clinicians
and caregivers have strategies to implement in lieu of
antipsychotic medications if dementia behaviors re-
emerge or persist. Although there are numerous studies
evaluating various non-pharmacological strategies to re-
duce antipsychotic medications use or address dementia
behaviors, much of the evidence for the effectiveness of
these interventions is insufficient [14]. Furthermore, com-
plex, labor-intensive interventions that might substitute
for antipsychotics can be difficult to implement with exist-
ing staff and resources. Indeed, many interventions that
reveal a positive effect in small- scale studies implemented
by research staff have difficulty showing similar effects in
real-world replications. Additionally, some researchers
argue that rigorously testing such interventions may be
difficult, in part because it is not possible to blind nursing
home clinicians to interventions.
Cluster-randomized trial methods are one methodo-
logical approach to overcome research limitations for
testing strategies to reduce antipsychotic medication use
or improve the behavioral and psychological symptoms
of dementia using non-pharmacological approaches. By
randomizing NHs to implement antipsychotic medica-
tion practice guidelines, for example, or to serve as
control sites, we can rigorously test such interventions
using pragmatic methods. At Brown University, we use
cluster-randomized trials to conduct studies on topics
such as influenza vaccination [15, 16]; others have used
these methods for antipsychotic medication reduction
interventions [17–19]. The Brown studies pair cluster-
randomized trial methods with the use of existing
clinical and administrative data, such as United States
Minimum Data Set resident assessment data; this
allows us to conduct rigorous nursing home research
efficiently. We suggest that others use similar ap-
proaches and data sources, e.g., the Minimum Data Set
or InterRAI assessment tools [20], to test antipsychotic
medication interventions using approaches that mimic
real-world conditions. One such trial is currently un-
derway in Ontario, offering a model for others around
the developed world [21].
Fig. 1 Percent of United States nursing home residents on antipsychotic medications without a psychiatric diagnosis, 2000–2010
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Conclusions
Despite widespread agreement that nursing homes’
use of antipsychotic medications as chemical re-
straints is associated with poor clinical outcomes and
as such constitutes a marker of poor quality of care,
prevalence remains high and variation suggests con-
tinued opportunity to improve care even in countries,
like the United States, that have long-standing policies
designed to decrease APM use. While we agree with
Frankenthal et al. [7] that regulation and public
reporting can help to decrease prevalence, the United
States experience suggests that nursing home clinicians
and caregivers also need effective alternative interventions
to employ as substitutes for antipsychotics. We suggest
expanded use of cluster-randomized trials to test
strategies to remove residents from antipsychotics and
to implement alternate, non-pharmacological approaches
for addressing the behavioral and psychological symptoms
of dementia.
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